Multifunctional yolk/shell-structured hybrid nanomaterials have attracted increasing interest as theranostic nanoplatforms for cancer imaging and therapy. However, because of the lack of suitable surface engineering and tumor targeting strategies, previous research has focused mainly on nanostructure design and synthesis with few successful examples showing active tumor targeting after systemic administration. In this study, we report the general synthetic strategy of chelator-free zirconium-89 ( 89 Zr)-radiolabeled, TRC105 antibody-conjugated, silica-based yolk/shell hybrid nanoparticles for in vivo tumor vasculature targeting. Three types of inorganic nanoparticles with varying morphologies and sizes were selected as the internal cores, which were encapsulated into single hollow mesoporous silica nanoshells to form the yolk/shell-structured hybrid nanoparticles. As a proof-of-concept, we demonstrated successful surface functionalization of the nanoparticles with polyethylene glycol, TRC105 antibody (specific for CD105/endoglin), and 89 Zr (a positron-emitting radioisotope), and enhanced in vivo tumor vasculature-targeted positron emission tomography imaging in 4T1 murine breast tumor-bearing mice. This strategy could be applied to the synthesis of other types of yolk/shell theranostic nanoparticles for tumortargeted imaging and drug delivery.
Introduction
Despite great challenges in the clinical translation of nanomedicine [1] [2] [3] , scientists worldwide are devoting great efforts in searching for various types of multifunctional nanomaterials to improve future cancer management. The last decade has witnessed an unprecedented expansion in the design, synthesis, and preclinical applications of various kinds of nanomaterials [4, 5] . Among them, silica-based hybrid nanoparticles have shown immense potential in targeted Nano Res. 2018, 11 (9) : 4890-4904 cancer diagnosis and therapy [6, 7] . Silica, or silicon dioxide, is "generally recognized as safe" by the U.S. Food and Drug Administration (ID Code: 14808-60-7) [8] . To date, the silica-shell-coating strategy remains one of the most used, economical, and practical techniques for the design and synthesis of hybrid nanomaterials [9] . Ultra-small dye-encapsulated fluorescent silica nanoparticles, known as C dots (or "Cornell dots"), entered clinical trials in January 2011 (NCT01266096, NCT02106598) [10, 11] . These "target-or-clear" hybrid silica nanostructures (< 10 nm) are encapsulated with near-infrared (NIR) dyes (e.g. Cy5), tumor-homing peptides (e.g. cRGDY), and radioisotopes (e.g. iodine-124 ( 124 I, t 1/2 = 100.8 h) and zirconium-89 ( 89 Zr, t 1/2 = 78.4 h)), allowing for positron emission tomography (PET)-/ optical dual-modality-targeted imaging of cancer [10, [12] [13] [14] . Besides its high clinical translational potential, silica is also known as a versatile nanoplatform for intrinsic radiolabeling [15, 16] . Recently, we and others have successfully developed a silica-based intrinsic radiolabeling technique for isotopes of 89 Zr [15, 16] , copper-64 ( 64 Cu, t 1/2 = 12.7 h) [17] , arsenic-72 ( 72 As, t 1/2 = 26 h) [18] , and titanium-45 ( 45 Ti, t 1/2 = 3.1 h) [19] , to name a few.
Biocompatible porous silica nanoparticles, such as mesoporous silica nanoparticles (MSNs), with a relatively larger particle size (> 50 nm) than that of C dots (< 10 nm) have been attractive drug delivery systems because of their high specific surface area and pore volume [20] [21] [22] [23] [24] . By introducing a large cavity inside each original MSN, hollow mesoporous silica nanoparticles (HMSNs) have attracted increasing interest as a new drug delivery system with greatly enhanced drug loading capacity [25, 26] . To further integrate other optical or magnetic functionalities, a new type of hybrid nanomaterial, named yolk/shell-structured nanoparticles, has also been developed [27] [28] [29] [30] [31] [32] [33] . Each hybrid nanoparticle possesses an inorganic functional core for imaging or therapy, a large cavity for the storage of chemotherapeutic drugs, and a thin mesoporous silica shell with tunable pore size for facilitating the loading and release of the pre-loaded drugs [34] .
Efficient targeting of these silica-based hybrid nanomaterials to the tumor site is critical. The focus of previous research on yolk/shell-structured nanoparticles was mainly on the nanoparticle design and synthesis [8, 35, 36] . However, because of the lack of suitable surface engineering and tumor targeting strategies, very few of them showed the capability of in vivo whole-body biodistribution and active tumor-targeted imaging. Tumor vessels are known to have high vascular permeability and lack functional lymphatics because of the uncontrolled growth rate and changes in endothelial cell shape, resulting in the accumulation of various nanoparticles (typically smaller than 300 nm) in tumor tissues based on the enhanced permeability and retention (EPR) effect [37] . Tumor vasculature targeting (i.e. targeting receptors overexpressed on tumor vascular endothelial cells) is a generally applicable targeting strategy for a wide variety of nanoparticles regardless of tumor type [38] . By targeting CD105 (also known as endoglin, which is an ideal marker that is almost exclusively overexpressed on proliferating endothelial cells [39] ), we have demonstrated the broad potential of CD105-targeted nanomaterials in cancertargeted imaging and therapy using TRC105, a human/ murine chimeric IgG1 monoclonal antibody that binds to both human and murine CD105 [40] , or its fragments as the targeting moieties [23, 25, [41] [42] [43] .
In this work, we report the general synthesis strategy of chelator-free 89 Zr-radiolabeled, TRC105-conjugated, silica-based yolk/shell hybrid nanoparticle for in vivo tumor vasculature targeting. Three types of inorganic nanoparticles with varying morphologies and sizes were selected as the internal cores, which were encapsulated into single HMSNs to form the yolk/shell-structured hybrid nanoparticles. As a proof-of-concept, we showed the successful post-surface functionalization of the nanoparticles with polyethylene glycol (PEG), TRC105, and 89 Zr, and demonstrated the in vivo tumor vasculaturetargeted PET imaging in 4T1 murine breast tumorbearing mice. This strategy could be applicable to the synthesis of other types of yolk/shell nanoparticles, creating an attractive multifunctional nanoplatform for tumor-targeted imaging and drug delivery.
Results and discussion

General synthesis of multi-functional yolk/ shell-structured hybrid nanomaterials
As shown in Scheme 1, the general synthesis of yolk/ Nano Res. 2018, 11 (9) : 4890-4904 Scheme 1 General synthesis of multi-functional yolk/shell-structured hybrid nanomaterials. Pre-prepared inorganic functional nanocrystal (1, such as UCNP, SPION, or QD) was selected as the core and coated with dense silica to form core@dSiO 2 (2) . The nanoparticle was further coated with another layer of mesoporous silica nanoshell, forming core@dSiO 2 @MSN (3). A selective etching strategy was then introduced to selectively etch the dSiO 2 layer while leaving the MSN layer intact, forming core@HMSN (4, where HMSN stands for hollow mesoporous silica nanoshell). Because of the presence of abundant silanol groups (-Si-OH) on the surface and inside the meso-channels of core@HMSN, 89 shell-structured tumor vasculature-targeted silica-based hybrid nanoparticles started with a surfactant-stabilized (e.g. oleic acid) inorganic functional nanoparticle (e.g. upconversion nanoparticle (UCNP), superparamagnetic iron oxide nanoparticle (SPION), or quantum dot (QD)) as the internal core. Subsequently, an oil-in-water reverse micro-emulsion silica coating approach was introduced to uniformly coat each hydrophobic nanoparticle core with a thickness-controllable and biocompatible non-porous silica interlayer. This step will facilitate the coating of the third porous silica outer layer with the presence of template surfactants (e.g. cetyltrimethylammonium chloride solution, or CTAC). A selective silica etching protocol was then adopted to carefully etch out the non-porous silica interlayer, leaving a cavity inside each ~ 100-nm yolk/shell nanoparticle. Afterwards, a silica-based chelator-free 89 Zr labeling strategy was employed to stably radiolabel the nanoparticle with 89 Zr for in vivo whole-body PET imaging. The radiolabeled nanoparticles were then surface-PEGylated and functionalized with TRC105 to improve stability in the bloodstream and specific targeting of CD105 in the tumor vasculature.
Synthesis of UCNP@HMSN hybrid nanoparticles
UCNPs have gained growing interest owing to their unique upconversion luminescence features that are highly suitable for multimodal imaging in living subjects [44] . After excitation using a 980-nm laser, UCNPs exhibited attractive optical features, such as sharp emission lines [45] , long lifetimes (~ ms) [46] , large anti-Stokes shift [45] , superior photo-stability [47] , high detection sensitivity [48] , non-blinking and non-bleaching [47, 49] , deeper tissue penetration depth [50] , minimal photo-damage [51] , and extremely low auto-fluorescence [52] . In this study, we synthesized uniform ~ 25-nm UCNPs of β-NaYF 4 :Tm/Yb (2/20 mol%) ( Fig. 1(a) ) using a modified procedure that has been reported previously [53, 54] . The inset in Fig. 1(a) shows a digital photo of β-NaYF 4 :Tm/Yb (suspended in cyclohexane) emitting ultraviolet (UV), blue, and NIR light after excitation with a 980-nm laser (only the blue light was captured by a digital single-lens reflex (DSLR) camera). As-synthesized UCNPs were then coated with a dense silica (dSiO 2 ) shell in an oil-in-water reverse micro-emulsion system [55] . Figure 2 the transmission electron microscopy (TEM) image of ~ 78-nm UCNP@dSiO 2 . The thickness of the dSiO 2 layer was estimated to be ~ 14 nm. The delivery rate of tetraethyl orthosilicate (TEOS) during the synthesis Nano Res. 2018, 11 (9) : 4890-4904 of UCNP@dSiO 2 was found to have significant impact on the yield of UCNP@dSiO 2 , which was carefully controlled at 100 μL·h −1 using a syringe pump to avoid aggregation and homogeneous nucleation of silica [55] .
The introduction of the dSiO 2 layer is critical for the successful formation of the yolk/shell nanostructure. It not only facilities the growth of the third porous silica layer, but also serves as a hard template that will later be selectively etched out to form the cavity. To grow the third porous silica layer, as-synthesized UCNP@dSiO 2 suspended in deionized water were mixed with CTAC, triethanolamine (TEA), and TEOS. A slow and controllable TEOS delivery procedure (rate: 40 μL·min −1 ) was again used in this case with a syringe pump. Figure 1 (c) shows the TEM image of ~ 100-nm UCNP@dSiO 2 @MSN. The inset is a single UCNP@dSiO 2 @MSN showing the UCNP core (the inner dark dot), the first dSiO 2 layer (middle layer with a lighter color), and the second MSN layer (the outermost layer with the lightest color). The thickness of the third porous silica layer was found to be ~ 11 nm.
Before performing any nanoparticle purification procedures, the reaction system was cooled down to 50 °C , followed by the addition of sodium carbonate (Na 2 CO 3 ), and kept under constant stirring for 30-70 min to selectively etch out the dSiO 2 interlayer, forming yolk/shell-structured UCNP@HMSN, as shown in Fig. 1 
(d).
The final average size of UCNP@HMSN was measured to be ~ 115 nm. The surfactant CTAC was later removed via an extraction process by stirring the nanoparticles in a 1 wt.% solution of NaCl in methanol [56] . The pore size of the nanoparticle porous silica layer was 2-3 nm, similar to that of previously reported MSNs [23] .
Optimization of the selective silica etching procedure
Cationic surfactants (in our case, CTAC) play vital roles in the formation of the yolk/shell nanostructure. It is important to note that CTAC needs to stay in the MSN network to ensure successful selective etching of dSiO 2 . During the etching process, positively charged free cetyltrimethylammonium cations (CTA + ) will first adsorb to the surface of UCNP@dSiO 2 @MSN(CTAC) via electronic attraction. Subsequently, with the presence of Na 2 CO 3 in the solution and CTAC in the MSN shell, selective etching of silica from the dSiO 2 core starts and will be accelerated by the surrounding free CTAC, forming uniform UCNP@HMSN(CTAC) after the redeposition process [57] . The effective etching of the dSiO 2 interlayer was demonstrated to be highly dependent on the free CTAC concentration, etching temperature, and etching time, as we reported previously [25] . To avoid over-etching, the optimal etching temperature was fixed to be 50 °C 
Synthesis of other types of yolk/shell hybrid nanomaterials with irregularly shaped cores
To demonstrate the general applicability of the abovementioned strategy, we extended the uniform 25-nm UCNP cores to other nanoparticles with irregular shapes and smaller sizes. Oleic acid-capped SPIONs with an average particle size of 8-10 nm were synthesized based on a previously reported thermal decomposition approach [55, 58] . As shown in Fig. 3(a) , as-synthesized SPIONs had a relatively broad size distribution and non-spherical morphology. The inset in Fig. 3(a) shows the clear superparamagnetism of SPIONs suspended in cyclohexane at room temperature. The third functional nanocrystal core we selected was the commercially available organic QD705 (1 μM in decane, purchased from Life Technology). A representative TEM image of QD705 (Fig. 3(d) ) revealed a rod-shaped QD705 with dimensions of ~ 6.5 nm × ~ 13 nm. The inset in Fig. 3(d) is a photo showing the optical imaging (Em = 700 nm) of QD705 under blue light excitation (Ex = 465 nm) using an IVIS Spectrum imaging system. Successful formation of monodispersed yolk/shellstructured SPION@HMSN and QD705@HMSN was found to be highly dependent on the dSiO 2 coating step (Figs. 3(b) and 3(e)), where severe nanoparticle aggregation should be avoided to improve the yield Nano Res. 2018, 11 (9) : 4890-4904 and stability of the final hybrid nanoparticles (Fig. S1 in the Electronic Supplementary Material (ESM)). The final sizes of SPION@HMSN and QD705@HMSN measured by TEM were ~ 77 and ~ 67 nm, respectively, which were significantly smaller than the ~ 115-nm UCNP@HMSN. Because of the smaller core size and greater difficulties in achieving monodispersed core@dSiO 2 nanoparticles, higher yields of twins and triplets (Figs. 3(c) and 3(f)) were observed in these two cases when compared with UCNP@HMSN (as shown in Fig. 1(d) ). Taken together, we demonstrated the successful extension of the yolk/shell hybrid nanoparticle synthesis to other functional (magnetic and optical) nanoparticles with varying sizes and morphologies.
Surface functionalization of UCNP@HMSN for in vitro CD105 targeting
To demonstrate the active targeting of a representative yolk/shell hybrid nanomaterial, as-synthesized uniform UCNP@HMSN were selected and subjected to postsurface functionalization, which included amination, PEGylation, and antibody conjugation based on previously reported procedures [23, 25, 43] . Without suitable PEGylation, the highly negatively charged UCNP@HMSN could form severe aggregation in phosphate-buffered saline (PBS) within minutes. The stability was significantly improved after surface PEGylation. The hydrodynamic diameter (HD) of the final UCNP@HMSN-PEG 5k -TRC105 was measured to be 171.9 ± 1.2 nm by dynamic light scattering (DLS), as shown in Fig. 4(a) .
Before in vivo investigation, human umbilical vein endothelial cells (HUVECs, CD105-positive) were subjected to flow cytometry to confirm the in vitro CD105 targeting efficiency of the non-radioactive UCNP@HMSN-PEG 5k -TRC105. Because of the lack of a 980-nm excitation light source in the BD FACSCalibur four-color analysis cytometer, which was equipped with 488-nm and 633-nm lasers, NHS-fluorescein was conjugated to the surface of the nanoparticles to facilitate the flow cytometry study. The results from dose of TRC105 (500 μg·mL −1 , blocking group) only yielded minimal fluorescence enhancement via nonspecific binding.
Chelator-free 89 Zr labeling and in vivo CD105-targeted PET imaging
Zr 4+ is a hard Lewis acid and thus prefers hard Lewis bases as donor groups. Previously, we demonstrated that the deprotonated silanol groups (-Si-O -), which originated from the hydrolysis and condensation of TEOS [59] , could function as hard Lewis bases for stable chelator-free 89 Zr labeling of silica-based nanoparticles [15] . Approximately 2-3 million -Si-OH groups in each 150-nm MSN was estimated based on our previous research [15] . For typical chelator-free radiolabeling, aminated UCNP@HMSN (or UCNP@HMSN-NH 2 , concentration: ~ 1 mg·mL MBq) of 89 Zr-oxalate at 75 °C for 3 h. The final pH of the mixture was carefully re-adjusted to 7-8 with 2 M Na 2 CO 3 . The labeling yield was found to be greater than 80% after labeling at 75 °C for 3 h. The yield continued to increase over time and reached > 90% after 22 h of incubation (Fig. 4(c) and Table S1 in the ESM). Such 89 Zr labeling was also found to be concentrationand temperature-dependent, with higher concentration and incubation temperature giving higher labeling yield, similar to what we have observed previously [15] . For example, slightly reduced labeling yield over time was achieved by lowering the labeling temperature to 37 °C , as shown in Table S2 in the ESM. To further demonstrate the role of deprotonated silanol groups in chelator-free 89 Zr labeling, the pH of the labeling solution was adjusted to near the isoelectric point of silica, which is approximately 2, to ensure protonation of the silanol groups as -Si-OH. As expected, the 89 Zr labeling yield was almost completely inhibited, Nano Res. 2018, 11 (9) : 4890-4904 with the maximal labeling yield found to be lower than 2%, as shown in Table S1 In vivo tumor-targeted PET imaging was then carried out in 4T1 murine breast tumor-bearing mice, which express high levels of CD105 in the tumor neovasculature [60] . Each mouse was injected with 5-10 MBq of 89 Zr-labeled yolk/shell nanoparticles, and time points of 0.5, 6, 24, and 48 h post-injection (p.i.) were chosen for serial PET scans to show the in vivo biodistribution patterns of tumor-bearing mice from targeted, nontargeted, and blocking groups (Fig. 5) . Quantitative data obtained from region-of-interest (ROI) analysis of these PET images are also shown in Fig. 5 and Tables S3-S5 in the ESM. The circulation of the 89 Zr-labeled nanoparticles in all three groups was indicated by the dominant radioactivity signal in mouse heart (or blood) at 0.5 h p.i., with the radioactivity signal in the heart ranging from 22.6 %ID·g −1 (percentage of the injected dose per gram) to 30.5 %ID·g −1 (Tables S3-S5 in the ESM). The clearance of the nanoparticles from blood to the liver and spleen was also observed among these groups, with a clear decrease in radioactive signal in the bloodstream and rapid accumulation of nanoparticles in the mouse reticuloendothelial system (RES) (Fig. 5) . The blood circulation half-life of UCNP@[ Table S3 in the ESM (n = 3). In contrast, without the conjugation of TRC105 (i.e. passive targeting alone), the 4T1 tumor uptake of uptake found to be 20.7 ± 0.7 %ID·g −1 at 0.5 h p.i., and further increased to 32.3 ± 4.9 %ID·g −1 at 48 h p.i. for the targeted group (n = 3, Fig. 6(a) and Table S3 in the ESM). The maximal liver uptake was found to be even higher for the non-targeted (54.9 ± 2.7 %ID·g −1 at 48 h p.i., Fig. 6(b) and Table S4 in the ESM) and blocking group (46.9 ± 3.6 %ID·g −1 at 48 h p.i., Fig. 6 (c) and Table S5 in the ESM). 
Conclusion
In conclusion, to address the challenges in the synthesis, whole-body biodistribution, and in vivo active tumor targeting of silica-based hybrid nanoparticles, we report the general synthesis of three types of uniform yolk/ shell-structured nanoparticles and present the chelatorfree radiolabeling and in vivo tumor vasculature-targeted PET imaging of UCNP@[
89 Zr]HMSN-PEG 5k -TRC105 in 4T1 tumor-bearing mice. Vascular targeting led to > 2-fold enhancement in tumor uptake compared to that of passive targeting alone based on the EPR effect (~ 10 %ID·g −1 vs. ~ 5 %ID·g
−1
). Despite great challenges in the clinical translation of nanomedicine, we believe that the reported strategy might provide a highly valuable tool for scientists to create other attractive yolk/shell-structured multifunctional nanoplatforms for future tumor-targeted imaging and image-guided drug delivery. Nano Res. 2018, 11(9): 4890-4904
Methods
Materials
TRC105 was provided by TRACON Pharmaceuticals Inc. (San Diego, CA). Chelex 100 resin (50-100 mesh), tetraethyl orthosilicate (TEOS), triethanolamine (TEA), (3-aminopropyl)triethoxysilane (APTES), cetyltrimethylammonium chloride solution (CTAC, 25 wt.%), absolute ethanol, sodium chloride (NaCl), sodium hydroxide (99.99%), oleic acid, 1-octadecene (technical grade, 90%), ammonia, yttrium(III) chloride hexahydrate, ytterbium(III) chloride hexahydrate, thulium(III) chloride, Igepal CO-520, and ammonium fluoride were obtained from Sigma-Aldrich and used without further purification. Iron chloride hexahydrate (FeCl 3 ·6H 2 O, > 99%) was purchased from Acros. PD-10 columns were purchased from GE Healthcare (Piscataway, NJ). SCM-PEG 5k -Mal was obtained from Creative PEGworks. QD705 (1 μM in decane) was purchased from Life Technology. Water and all buffers were of Millipore grade and pretreated with Chelex 100 resin to ensure that the aqueous solution was free of heavy metals.
Synthesis of oleic acid-capped upconversion nanoparticles (NaYF 4 :Tm/Yb)
Uniform-sized NaYF 4 :Tm/Yb UCNPs were synthesized via a modified procedure that was reported previously [53, 54] . In a typical synthesis of 25-nm β-NaYF 4 :Tm/Yb (2/20 mol%), YCl 3 ·6H 2 O (473.24 mg, 1.56 mmol), YbCl 3 · 6H 2 O (155 mg, 0.4 mmol), and TmCl 3 ·6H 2 O (11 mg, 0.04 mmol) in deionized water were added to a 100-mL flask containing 15 mL of oleic acid and 30 mL of 1-octadecene. The solution was then stirred at room temperature for 1 h. Afterwards, the mixture was slowly heated to 120 °C to remove water under an argon atmosphere. The solution was maintained at 156 °C for approximately 30 min until a homogeneous transparent yellow solution was obtained. The system was then cooled down to room temperature in argon. Subsequently, 10 mL of methanol solution of NH 4 F (296.3 mg, 8 mmol) and NaOH (200 mg, 5 mmol) was added, and the solution was stirred at room temperature for another 2 h. After methanol was evaporated, the solution was heated to 290 °C and kept for 2 h before it was cooled down to room temperature. The resulting nanoparticles were precipitated by the addition of 20 mL of ethanol and collected by centrifugation at 10,000 rpm for 10 min. The product was re-dispersed with 5 mL of cyclohexane and precipitated again by adding 15 mL of ethanol, then collected by centrifugation at 10,000 rpm for 10 min. After four washes, the final product was well dispersed in 20 mL of cyclohexane.
Synthesis of oleic acid-capped SPIONs
A previously reported two-step synthetic approach [55, 58] was used in this work for the synthesis of SPIONs.
Step 1: synthesis of iron-oleate complex
Iron-oleate complex was used as the precursor for the synthesis of SPIONs. FeCl 3 ·6H 2 O (3.243 g, 12 mmol) and NaOH (1.44 g, 36 mmol) were dissolved in methanol (40 mL) under magnetic stirring. Oleic acid (12 mL, 36 mmol) was added to the FeCl 3 -methanol solution, followed by addition of NaOH-methanol solution using a separatory funnel. The mixture was stirred overnight at room temperature. A reddish-brown product was found at the bottom of the mixture the next morning. The product was washed twice with methanol and twice with deionized water before it was dried at room temperature for 48 h. The final iron-oleate complex was obtained in a waxy solid form.
Step 2: synthesis of SPIONs
In a typical synthesis of 8-10 nm SPIONs, pre-prepared iron-oleate (2.9 g, ~ 3 mmol) was dissolved in 1-octadece (40 mL). The mixture was first heated to 80 °C to accelerate the dissolution of solid iron-oleate. It was then heated to 120 °C and maintained at this temperature for 2 h to remove air and water in the system. The reaction mixture was then directly heated to 300 °C and kept for 30 min. No extra oleic acid was used during the synthesis process. The black-brown mixture was cooled down to room temperature, washed with hexane and ethanol, and separated by magnetic separation. The final product was well dispersed in cyclohexane.
Synthesis of UCNP@HMSN
A three-step synthetic procedure was employed for the synthesis of UCNP@HMSN (or SPION@HMSN, QD@ Nano Res. 2018, 11 (9) : 4890-4904 HMSN).
Step 1: synthesis of UCNP@dSiO 2
To synthesize dense silica-coated UCNP (UCNP@dSiO 2 ) with a ~ 14-nm silica shell, Igepal CO-520 (NP-5, 2 mL) was dispersed in cyclohexane (40 mL) in a 100-mL three-necked flask and stirred for 5 min. Subsequently, oleic acid-capped UCNPs in cyclohexane solution (1 mL) was added into the cyclohexane/NP-5 mixture and stirred for 2 h at room temperature. Further, ammonia (280 μL, 30%) was added, and the system was sealed and stirred for another 2 h. TEOS (400 μL) was then delivered into the system at a rate of 100 μL·h −1 using a syringe pump. The mixture was sealed and kept under magnetic stirring for 48 h at room temperature before adding methanol to collect the nanoparticles. The product was precipitated with excess hexane and collected by centrifugation. The nanoparticles were re-dispersed in ethanol under ultrasonic treatment, precipitated with excess hexane, and collected by centrifugation. The process was repeated at least three times to completely remove the excess NP-5. The as-obtained UCNP@dSiO 2 were well-dispersed in ethanol or deionized water.
Step 2: synthesis of UCNP@dSiO 2 @MSN
CTAC (2 g) and TEA (20 mg) were dissolved in 20 mL of high Q water and stirred at room temperature for 1 h. Subsequently, 10 mL of as-synthesized UCNP@dSiO 2 solution in water was added and stirred at room temperature for 1 h before the addition of 0.2 mL of TEOS using a syringe pump at 40 μL·min −1 . The mixture was stirred for 1 h at 80 °C in a water bath to form UCNP@dSiO 2 @MSN.
Step 3: selective etching of the dSiO 2 interlayer to form UCNP@HMSN
The reaction system was cooled down to 50 °C followed by the addition of 636 mg of Na 2 CO 3 and kept under constant stirring for 30-70 min to selectively etch out the dense silica layer, forming UCNP@HMSN. To remove the CTAC, the product was extracted for 24 h with a 1 wt.% solution of NaCl in methanol at room temperature. This process was carried out at least three times to ensure complete removal of CTAC. A similar three-step procedure was used for the synthesis of SPION@HMSN and QD@HMSN.
4.5
89 Zr production 89 Zr-oxalate was produced according to previous procedures by the University of Wisconsin-Madison cyclotron group [67] . Briefly, natural yttrium-89 ( 89 Y) foil (250 μm, 99.9%) was irradiated with a proton beam to create 89 Zr via the 89 Y(p,n) 89 Zr reaction using a 16-MeV GE PETtrace cyclotron (the actual proton beam energy used was ~ 13.8 MeV). After isotope separation and purification, 89 Zr-oxalate was obtained with a specific activity of > 20 GBq·μmol −1 of Zr.
Intrinsic 89 Zr labeling of UCNP@HMSN
The intrinsic radiolabeling of UCNP@HMSN with 89 Zr was based on the strong interaction between 89 Zr 4+ and the abundant deprotonated silanol groups (-Si-O − ) from the HMSN shell [15] . For typical labeling, 250 μL of UCNP@HMSN at ~ 1 mg·mL −1 were suspended in HEPES buffer (pH 7.5, 0.1 M) and mixed with 3 mCi (or 111 MBq) of 89 Zr-oxalate at 75 °C for 3 h. The final pH of the mixture was carefully re-adjusted to 7-8 using 2 M Na 2 CO 3 . The labeling yield was found to be greater than 80% after labeling at 75 °C for 3 h. As-synthesized UCNP@[
89 Zr]HMSN could be easily collected by centrifugation at 21,000g for 10 min. After washing three times with water, the final radioactive nanoparticles were well suspended in deionized water.
Synthesis of UCNP@[ 89
Zr]HMSN-PEG 5k -TRC105 for tumor vasculature targeting
To prepare UCNP@[
89 Zr]HMSN-PEG 5k -TRC105, assynthesized UCNP@HMSN were first functionalized with -NH 2 groups using APTES, as reported previously [25] . Briefly, UCNP@HMSN were dispersed in 20 mL of absolute ethanol, followed by addition of 1 mL of APTES. The system was sealed and kept at 86-90 °C in a water bath for 24 h. Afterwards, the mixture was centrifuged and washed several times with ethanol to remove the residual APTES. As-synthesized UCNP@ HMSN-NH 2 was well dispersed in water, and the concentration of -NH 2 groups (nmol·mL 
Flow cytometry study
Cells were first harvested and suspended in cold PBS with 2% bovine serum albumin at 5 × 10 6 cells·mL −1
and incubated with fluorescein-conjugated UCNP@ HMSN-PEG 5k -TRC105 (targeted group) or fluoresceinconjugated UCNP@HMSN-PEG 5k (non-targeted group) for 30 min at room temperature. The same fluoresceinconjugated UCNP@HMSN-PEG 5k were used to prepare fluorescein-conjugated UCNP@HMSN-PEG5k-TRC105 (targeted group) and fluorescein-conjugated UCNP@ HMSN-PEG 5k (non-targeted group) in order to maintain the exact same fluorescein/nanoparticle ratio during the flow cytometry studies. The cells were washed three times with cold PBS and centrifuged for 5 min. Subsequently, the cells were washed and analyzed using a BD FACSCalibur four-color analysis cytometer, which is equipped with 488-nm and 633-nm lasers (Becton-Dickinson, San Jose, CA) and FlowJo analysis software (Tree Star, Ashland, OR). "Blocking" experiment was also performed in cells incubated with the same amount of fluorescein-conjugated UCNP@HMSN-PEG 5k -TRC105, where 500 μg·mL −1 unconjugated TRC105 was added to evaluate the specificity of fluoresceinconjugated UCNP@HMSN-PEG 5k -TRC105 toward CD105. The cells were also examined under a Nikon Eclipse Ti microscope to validate the results.
4T1 tumor model
All animal studies were conducted following a protocol approved by the University of Wisconsin Institutional Animal Care and Use Committee. To generate the 4T1 tumor model, 4-to 5-week-old female BALB/c mice were purchased from Envigo (Indianapolis, IN, USA), and tumors were established by subcutaneously injecting 2 × 10 6 cells, suspended in 100 μL of 1:1 mixture of RPMI 1640 and Matrigel (BD Biosciences, Franklin Lakes, NJ, USA), into the front flank of the mice. The tumor sizes were monitored every other day, and the animals were subjected to in vivo experiments when the tumor diameter reached 5-8 mm.
4.10
In vivo tumor vasculature-targeted PET imaging and biodistribution studies PET scans at various time points post-injection were performed using a microPET/microCT Inveon rodent model scanner (Siemens Medical Solutions USA, Inc.) Image reconstruction and region-of-interest analysis of the PET data were performed similar to previously described protocols [41, [68] [69] [70] [71] . Quantitative PET data were presented as %ID·g −1 . Tumor-bearing mice were each injected with 5- in vivo (blocking group). After the last PET scans at 48 h p.i., biodistribution studies were carried out. The mice were euthanized, and the blood, 4T1 tumor, and major organs/tissues were collected and wet-weighed. The radioactivity in the tissue was measured using a gamma-counter (Perkin-Elmer) and presented as %ID·g −1 (mean ± SD). Nano Res. 2018, 11 (9) : [4890] [4891] [4892] [4893] [4894] [4895] [4896] [4897] [4898] [4899] [4900] [4901] [4902] [4903] [4904] in the online version of this article at https://doi.org/ 10.1007/s12274-2078-9.
